Basic studies of oncogenesis have demonstrated that either the elevated production of particular oncogene proteins or the occurrence of qualitative abnormalities in oncogenes can contribute to neoplastic cellular transformation. The purpose of this study was to identify unique oncogenes that are differentially expressed in human cancers and characterize their functions in tumorigenesis. To discover new putative oncogenes, the differential display RT-PCR method was applied using normal cervical tissues, cervical cancer cell lines, cervical cancer tissues, and metastatic tissues. We identified a new human cervical cancer oncogene HCCR-2 that was overexpressed in various human tumors including leukemia, lymphoma, and carcinomas of the breast, kidney, ovary, stomach, colon, and uterine cervix. Ectopic expression of HCCR-2 resulted in direct tumorigenic conversions of NIH/3T3 and Rat1 fibroblasts. Nude mice injected with NIH/3T3 cells stably transfected with HCCR-2 formed tumors in 4 weeks. The resultant tumors display characteristics of an epithelial carcinoma. In HCCR-2 transfected NCI-H460 cells and RKO cells, stabilization of the p53 tumor suppressor occurred without genetic mutation and correlated with functional impairment, as indicated by the defective induction of p53-induced p21 WAF1 , MDM2, and bax. These results indicate that HCCR-2 probably represents a new oncogene that is related to tumorigenesis, functioning as a negative regulator of the p53 tumor suppressor.
Introduction
The identification of molecular alterations in cancerous and precancerous cells has provided insight into the role of oncogenes and tumor suppressor genes in tumor initiation and progression (Weinberg, 1994) . Oncogenes are derived from highly conserved proto-oncogenes that are altered by chromosomal point mutations, gene amplifications, or gene rearrangements (Bishop, 1991) . Structural alteration of proto-oncogenes leads to a quantitative or qualitative change in the expression of the corresponding protein product. The signal transduction pathways subverted by oncoproteins govern fundamental cell functions, including proliferation, cell cycle regulation, and apoptosis (Cooper, 1995) .
Although genetic characterization of tumor tissues demonstrates that mutation of the p53 gene is the most common genetic alteration in human cancers, the mutation ratio of the p53 gene in cervical cancer is relatively low (Crook et al., 1992; Busby-Earle et al., 1994) . It suggests that there are other oncogenes involved in cervical carcinogenesis. We applied the differential display RT-PCR method to discover genes involved in tumorigenesis of human cervical tissue, and identified the new human cervical cancer oncogene HCCR-2, which exhibits little similarity to other cDNAs in the database. Computer-assisted analyses indicated that HCCR-2 is markedly hydrophobic and possesses a characteristic single membrane-spanning domain and presecretory signal peptide.
The p53 tumor suppressor gene product is a shortlived transcription factor (Farmer et al., 1992) of target genes that regulates cell cycle check points (El-Deiry et al., 1993) . In most cases, the alterations within the coding sequences of the p53 tumor suppressor gene found in human cancers affect the DNA binding ability of p53. This fact indicates that p53 responsive genes are important in p53 tumor suppressor activity. In addition, interruption of the function of normal p53 at the protein level is also found in various tumors (Leonard et al., 1995) . Many oncoproteins of the DNA tumor viruses bind to p53 and disrupt p53 function. These include SV40 T-Antigen, adenoviral E1B, and human papilloma virus (HPV) E6, all of which bind directly to p53 (Sarnow et al., 1982; Wernes et al., 1990) . However, the manner in which the binding of these oncoproteins disrupts p53 function is different for each virus. Binding of HPV E6 inhibits p53 transcriptional activity and leads to rapid degradation of p53 that prevents accumulation of cellular p53 in response to DNA damage signals (Leonard et al., 1995) . On the other hand, SV 40 T-Antigen or adenoviral E1B binding results in interference with p53 transcriptional activity, while these bindings lengthen the half-life of p53 (Sarnow et al., 1982) .
In the present study, we screened a series of tissues from the same lineage, from normal cervical tissues, and from metastatic cervical tissues to identify oncogenes involved in tumorigenesis. We then investigated the oncogenic characteristics of the putative oncogene HCCR-2. We also determined whether the novel oncogene HCCR-2 is differentially expressed in cervical cancer tissues and other cancer tissues, and whether HCCR-2 is involved in the regulatory mechanism of p53 function.
Results and discussion
Identification and localization of the HCCR-1 and HCCR-2 genes Activation of proto-oncogenes plays an important role in the etiology of many tumors (Bishop, 1991; Weinberg, 1994; Cooper, 1995) . To identify oncogenes that may be responsible for the formation of cervical, and other cancers, we used differential display RT-PCR and identified the 206 bp partial cDNA fragment CC214. As shown in Figure 1a , among the multiple bands, CC214 was strongly expressed in cervical cancer tissue, metastatic lymph node tissue, and CUMC-6 cervical cancer cells, but not in normal cervical tissue.
Using the partial cDNA CC214 as a probe, we screened normal human lung, normal uterine cervical tissue, and the cervical cancer cDNA library to identify the full-length cDNA. Two clones with sizes of 2118 and 2003 bp were isolated from the human lung cDNA library. The longer clone, named HCCR-1 for human Figure 1 Identification and localization of HCCR-1 and HCCR-2. (a) Comparison of gene expression profiles by differential display PCR from total RNA isolated from normal cervical tissue, primary cervical cancer, cervical cancer tissue metastatic to lymph node and from CUMC-6 cervical cancer cell line. Differential display was carried out using 5 0 arbitrary primer H-AP21 (5 0 -AAGCTTTCTCTGG-3 0 ) and 3 0 H-T 11 C (5 0 -AAGCTTTTTTTTTTTC-3 0 ). The PCR products were resolved by electrophoresis. CC214 is the name of the partial HCCR-1 and HCCR-2 gene product. The arrow identifies the location relative to other PCR products. The shorter clone, named HCCR-2 for human cervical cancer-2 oncogene (GenBank Accession number AF 315598), encoded a polypeptide of 304 amino acids with a predicted molecular mass of 36 kDa.
Comparison of both sequences revealed that HCCR-2 corresponds to amino acids 57-360 of HCCR-1. HCCR-2 lacks exon 1 of HCCR-1 and is identical in sequence from nucleotides 129-2118 of HCCR-1, with the exception of an A : G substitution at nucleotide position 258 that results in an amino-acid change from isoleucine in HCCR-1 to valine in HCCR-2 (Figure 1c ). These results show that the two clones are normal alternative splicing forms because the sequences of 3 0 untranslated regions of HCCR-1 and HCCR-2 are exactly the same.
FISH analysis was used to identify the chromosomal location of HCCR-1 andHCCR-2. Results indicated that the location of both the HCCR-1 and HCCR-2 genes was chromosome 12q (Figure 1d ). We also confirmed the expression of HCCR-1 and HCCR-2 in cervical cancer tissues and the CUMC-6 cervical cancer cell line by conducting RT-PCR using specific HCCR primer (Figure 1e ).
HCCR-2 is involved in tumorigenesis and transdifferentiation of mouse NIH/3T3 cells
To determine whether HCCR-1 or HCCR-2 plays a role in tumorigenesis, we generated expression vectors containing full-length HCCR-1 or HCCR-2 cDNAs, transfected mouse NIH/3T3 cells and measured parameters of transformation. After mouse NIH/3T3 cells were transfected with HCCR-1 or HCCR-2 cDNAs, the transformation efficiencies (i.e., the number of foci per microgram of DNA transfected) were determined to be 0.8 (95% confidence intervals (CI), 10.9-13.1) and 2.5 (95% CI, 36.9-39.1), respectively ( Table 1 ). The transformation efficiency of ras gene used as a positive control was 1.2 (95% CI, 16.9-19.1). We also examined the transformation efficiency of HCCR-1 and HCCR-2 in Rat1 cells, and the results were similar to those in NIH/3T3 cells. Rat1 cells were transfected with HCCR-1 or HCCR-2 cDNAs and the transformation efficiencies were determined. The transformation efficiencies of HCCR-1, HCCR-2 and ras were 1.6 (95% CI, 22.5-24.8), 1.9 (95% CI, 26.9-29.1), and 1.8 (95% CI, 25.1-28.1), respectively (Table 2 ). These data suggest that HCCR-2 contained more potent detectable oncogenic activity than HCCR-1 and ras in both NIH/3T3 and Rat1 assay system. Comparable transfection with the control vector alone (nontransformed NIH/3T3 cells and Rat1 cells) yielded no transformation efficiency.
In all, 50 of the transformed foci (14 from HCCR-1 and 36 from HCCR-2) were isolated from the HCCR-1-or HCCR-2-transfected NIH/3T3 cells and were grown in semisolid soft-agar medium to measure colony formation efficiency. HCCR-2-transfected NIH/3T3 cells formed large colonies (4200 mm) with an efficiency of 29% in agar colony assays, whereas HCCR-1-transfected NIH3T3 cells formed colonies at low efficiency (12%).
We next examined whether HCCR-1 or HCCR-2-transfection forms tumors in nude mice. Six HCCR-1 and 11 HCCR-2-transfected clonal populations were selected from the soft-agar culture from different foci and injected into nude mice. Tumors were formed from 10 of 11 HCCR-2-injected nude mice in 4 weeks after injection. On the contrary, tumors were formed from only one of six HCCR-1-transfected mice after 2 months. These results indicate that cells expressing HCCR-2 are more tumorigenic than those expressing Transformed cell aggregates, foci, were counted by visual examination starting 2-3 weeks after transfection and the transformation efficiencies (i.e., the number of foci per microgram of DNA transfected) were determined Transformed cell aggregates, foci, were counted by visual examination starting 2-3 weeks after transfection and the transformation efficiencies (i.e., the number of foci per microgram of DNA transfected) were determined Novel human cervical cancer oncogene HCCR-2 J Ko et al HCCR-1. Therefore, we focused on the characterization of the novel oncogene HCCR-2.
NIH/3T3 cells, a differentiated fibroblast cell line (Aaronson et al., 1970) , are spindle shaped. As shown in Figure 2a and b, there were no discernible differences in cell morphology between wild-type NIH/3T3 cells and those transfected with the pcDNA3 vector alone. However, NIH/3T3 cells transfected with HCCR-2 showed polygonal shape with increased cellular volume compared to parental NIH/3T3 cells (Figure 2c ). A total of 10 HCCR-2-transfected NIH/3T3 stable transformants from colonies grown in soft agar were selected and HCCR-2 expression in stable transformants was confirmed by Western blot analysis using anti-HCCR-2 antibody ( Figure 2d ). HCCR-2 was not expressed in parental NIH/3T3 cells and those transfected with the pcDNA3 vector alone.
We also examined whether HCCR-2 causes the tumorigenic transformation of NIH/3T3 cells in nude mice. NIH/3T3 cells stably transfected with HCCR-2 were inoculated into 10 nude mice. All 10 nude mice injected with NIH/3T3 cells stably transfected with HCCR-2 showed 1.5-2. The tumors from nude mice injected with NIH/3T3 cells stably transfected with HCCR-2 display characteristics of epithelial carcinomas (Figure 3a) . Tumor sections from multiple mice revealed typical epithelial cell nests (arrows). The cell nests were enveloped by reticulin fibers (arrows) (Figure 3b ). For morphologic comparison between HCCR-2-derived tumor cells and epithelial cells, we determined whether HCCR-2-derived tumor cells express epithelial cell markers, such as keratin ( Figure 3c ) and epithelial membrane antigen (Figure 3d ), and the mesenchymal marker vimentin (Figure 3e ). NIH/3T3 cells stably transfected HCCR-2 expressed epithelial markers in vitro, whereas NIH/3T3 parental cells or cells transfected with pcDNA3 vector alone did not express these epithelial markers but expressed only vimentin (data not shown). Electron microscopy revealed that cultured tumor cells have microvilli ( Figure 3f ) and well-developed organelles (inset), and the tumor cells are connected by desmosomes (Figure 3g ). The presence of microvilli and desmosomes confirms that NIH/3T3 cells stably transfected HCCR-2 have acquired epithelial properties.
Differential expression of HCCR-2 in human cancers
Northern blot analysis was performed to examine the expression of HCCR-2 in human tissue using the CC214 partial cDNA fragment. HCCR-1 (B2.1 kb) and HCCR-2 (B2.0 kb) mRNAs were present in normal human tissues, including kidney, liver, skeletal muscle, heart, and brain tissues (Figure 4a ). The levels of mRNA expression were quantified by comparison with the levels of expression of b-actin. We also examined the expression of HCCR-2 in several cancer cell lines. HCCR-1 and HCCR-2 mRNAs were overexpressed in human leukemia and lymphoma cell lines, including chronic myelogenous leukemia cell line K-562, Burkitt's lymphoma cell line Raji, lymphoblastic leukemia cell line MOLT-4, promyelocytic leukemia cell line HL-60, and human cervical cancer cell line HeLa (Figure 4b) . The colon cancer cell line SW480, the lung cancer line A549, and the melanoma line G361 expressed low levels of HCCR-1 and HCCR-2. Although the HCCR-2 protein was also expressed in the Raji lymphoma cell line and the K-562 leukemia cell line, it was not expressed in normal leukocytes (Figure 4c ). Northern ( Figure 4d ) and Western (Figure 4e ) blot analyses revealed that fresh primary human tumor tissues, including carcinomas of the breast, kidney, ovary, and stomach, showed increased expression of HCCR-2 when compared with their normal counterparts.
To identify the cellular component responsible for the expression of HCCR-2, we performed in situ hybridization of cervical cancer tissue. As shown in Figure 5a , HCCR-2 was expressed in cervical cancer tissue. No signal was detected in surrounding normal tissues. We also conducted an immunohistochemical analysis. Immunohistochemical staining showed that immunoblastic-type malignant lymphoma cells were immunoreactive in the cytoplasm (Figure 5b ). Chronic myelogenous leukemic cells showed positive cytoplasmic staining for HCCR-2 (Figure 5c ). Breast adenocarcinoma tissue showed positive cytoplasmic staining (Figure 5d ). Colon adenocarcinoma (Figure 5e ) and squamous carcinoma of the uterine cervix (Figure 5f ) both showed positive cytoplasmic staining. Five tumor specimens of each type were examined. Corresponding normal tissues were not stained for HCCR-2 (data not shown).
Increased expression of HCCR-2 relative to normal tissue was detected in multiple tumor tissues, including breast, kidney, ovary, stomach, and colon carcinomas and from leukemia and lymphoma samples. Although further investigation with larger sample sizes will be needed, these results indicate that increased expression 
HCCR-2 is involved in p53 stabilization
Alterations within the coding sequences of the p53 tumor suppressor gene are the most common genetic changes in human cancers (Weinberg, 1991) . Therefore, we examined whether p53 expression was affected by overexpression of HCCR-2. As shown in Figure 6a , NCI-H460 cells transfected with the vector alone expressed a low level of the tumor suppressor protein p53. We also examined the expression level of p53 in HCCR-2 transfected RKO cells and vector transfected cells (Figure 6b ). However, levels of p53 were markedly elevated in HCCR-2 transfected cells both in NCI-H460 and RKO cells, compared to cells transfected with the vector alone. Increased levels of p53 may be associated with the presence of mutated p53 protein or an increase in protein stability. To investigate these two possibilities, we performed an RNA mismatch detection assay to examine possible p53 mutations. HCCR-2 stably transfected cells contained no mutations in exons 5-10 of the p53 transcript (data not shown). We next performed a pulse-chase analysis to evaluate protein stability. The half-life of p53 in 293 cells transfected with the vector alone was approximately 30 min ( Figure 6c , upper panel). By contrast, the half-life of p53 was more than 4 h in HCCR-2 stably transfected 293 cells (Figure 6c , lower panel). Results from the pulse-chase analysis and the RNA mismatch detection assay indicated that p53 was stabilized without genetic mutation.
The half-life of p53 in most normal primary cells ranges between 20 min and 1 h, although it varies in different cell types (Huibregtse et al., 1994) . Exposure of cells to DNA-damaging agents induces accumulation of the p53 protein and a lengthened half-life of four to fivefold without significant changes in the mRNA level (Hubert and Lambert, 1993) . As p53 is highly sensitive to ubiquitination dependent proteasomal degradation, post-translational regulation of p53 is probably largely (Sambrook et al., 1989) . Equivalent volumes of cell lysates containing 20 mg total protein were loaded on 10% SDS-polyacrylamide gels Novel human cervical cancer oncogene HCCR-2 J Ko et al dependent on a regulatory mechanism for ubiquitination and proteasomal degradation, although it is not clear how this regulation can be achieved in vivo. Our data showed that p53 stabilization occurred in HCCR-2 transfected NCI-H460 and RKO cells, indicating that HCCR-2 is probably involved in regulation of the modification of p53 with consequent stabilization of p53 through the interference of ubiquitination-dependent proteasomal degradation. Expression levels of several p53-associated proteins were also examined. p21 WAF1 is a well-known p53-dependent cdk inhibitory protein that functions in the response of most mammalian cells to DNA damage (Xiong et al., 1993) . Figure 6a and b shows that the level of p21 was decreased in HCCR-2 transiently transfected NCI-H460 and RKO cells, compared to cells transfected with the vector alone. Murine double minute 2 (MDM2) and bax genes, both possess p53 responsive elements (Momand et al., 1992; Oltval et al., 1993) . We also tested HCCR-2 overexpression for an effect on expression levels of these proteins. Results from the Western blot analysis showed that levels of MDM2, and bax were decreased in HCCR-2 transfected NCI-H460 cells and RKO cells, indicating that an increased level of p53 did not induce expression of these proteins, but did cause downregulated induction of these proteins (Figure 6a  and b) .
As shown in Figure 6d , we have performed a transient transfection assay whether HCCR-2 can stabilize an exogenous wild-type p53 and inhibit p53 activity. The results showed that HCCR-2 stabilized exogenous p53 and the level of p21 was reduced by HCCR-2. We also performed a luciferase assay using the native p21 promoter containing two p53 responsive elements to demonstrate that HCCR-2 can inhibit p53 to activate the p21 promoter. The results showed that HCCR-2 reduced p21 promoter activity in a dose-dependent manner.
Our results indicate that HCCR-2 probably participates in the negative regulation of p53 transcriptional activity and ubiquitin-dependent proteasomal degradation of p53. While further studies will be needed to characterize the cellular function and regulatory mechanism of HCCR-2, it is a potent oncogene in the development of many types of human cancers and is involved in p53 stabilization.
Materials and methods

Tissues and cell culture
Normal exocervical tissue specimens were obtained from uterine myoma patients during hysterectomy, and untreated primary cervical cancer and metastatic common iliac lymph node tissues were obtained during radical hysterectomy. Patient consent was obtained from each individual and the use of tissue samples was approved by the ethics committee of our institution. The human cervical cancer cell line CUMC-6 was isolated in our laboratory (Kim et al., 1996a) and maintained as a monolayer culture in Waymouth's MB 752/1 medium (Gibco, Grand Island, NY, USA) with 10% fetal bovine serum (FBS). Human embryonic kidney 293 cells were purchased from the American Type Culture Collection (Manassas, VA, USA) and cultured in Eagle's minimum essential medium (MEM) with 10% FBS. NIH/3T3 cells were cultured in Dulbecco's modified Eagle's medium (DMEM) with 10% FBS.
Establishment of the nude mice derived cell line
Tumor masses formed in the back of nude mice were held in ice-cold DMEM supplemented with 2 mm glutamine, 100 IU/ ml penicillin, 100 mg/ml streptomycin, and 20% FBS. After mechanical dissociation with crossed scalpels in ice-cold DMEM, tumor fragments and cellular suspensions were collected, washed three times with media, and finally centrifuged at 1000 g for 5 min. The sediments were resuspended in DMEM with 10% FBS and seeded into tissue culture flasks to initiate in vitro growth of the cells.
Differential display
Total RNA was extracted from tissues and cells using an RNA extraction kit (RNeasy total RNA kit; Qiagen Inc., Valencia, CA, USA) and 0.2 mg of total RNA was used to generate cDNA in a reverse transcription reaction (RNAimaget kit, GenHunter, MA, USA). With the use of the differential Figure 5 In situ hybridization and immunohistochemical staining. (a) In situ hybridization of cervical cancer tissue was conducted with an antisense riboprobe to detect HCCR-2 mRNA. We used digoxigenin for chromogen and hematoxylin stain for the counterstain. Staining was restricted to cervical cancer cell nests, which were surrounded by normal stroma. No signals were detected when sense probe was used as a negative control. Immunohistochemical staining for HCCR-2 expression using a polyclonal antibody generated against C-terminal HCCR-2 fusion protein of various human tumor tissues including lymphoma (b), leukemia (c), and carcinomas of breast (d), colon (e) and uterine cervix (f). We used aminoethyl carbozole for chromogen and hematoxylin stain for the counterstain. Original magnification,
Novel human cervical cancer oncogene HCCR-2 J Ko et al display kit (RNAimage TM kit), we performed PCR using oligodT primers and arbitrary sequences, each 13 bases in length according to the manufacturer's recommendations. After cDNAs of 3 0 termini of mRNAs were generated, the PCR products were separated by electrophoresis on a 6% denaturing polyacrylamide gel. Bands representing cDNAs of interest were excised from dried sequencing gel. The cDNAs were eluted in distilled water by boiling for 15 min and then were reamplified without [a-35 S]dATP, and with 20 mm dNTPs instead of 2 mm dNTPs. From the films, a 206 bp cDNA (referred to as CC214) was identified which was expressed in the primary cervical cancer tissue, metastatic lymph node and CUMC-6 cervical cancer cell line but not in normal cervical tissue. CC214 was identified by the use of 5 0 arbitrary primer H-AP21 (5 0 -AAGCTTTCTCTGG-3 0 ) and 3 0 H-T 11 C anchored primer (5 0 -AAGCTTTTTTTTTTTC-3 0 ) (GenHunter). CC214 Screening genomic DNA and fluorescence in situ hybridization (FISH)
Full-length HCCR-2 cDNA, labeled with [ 32 P] by random priming was used to probe a human placenta lambda genomic library (Stratagene, La Jolla, CA, USA) (Sambrook et al., 1989) . After screening the library by Southern blot analysis, a 20 kb genomic DNA clone containing the HCCR-1 or HCCR-2 gene was identified, and then the HCCR-1 or HCCR-2 genomic DNA was labeled with SpectrumReddUTP (Vysis, Downers Grove, IL, USA) by nick translation, and FISH analysis was performed as described (Cherif et al., 1990) .
To assign chromosomal localization, 0.5 ml of whole blood obtained from healthy volunteers was incubated with phytohemagglutinin (Life Technologies, Gaithersburg, MD, USA) for 72 h in DMEM with 10% FBS. Then peripheral blood lymphocytes were isolated and exposed to 0.1 mg/ml colcemid for 2 h to arrest the adequate numbers of mitoses. Cells were then exposed to a hypotonic solution consisting of 1 : 4 mixture of 1% sodium citrate and 0.075 M KCl for 30 min at 371C. After centrifugation at 1000 g for 5 min, cells were fixed with ice-cold glacial acetic acid: methanol (1 : 3 v/v). The chromosomes were dropped on a glass slide and incubated with the SpectrumRed-dUTP-labeled genomic DNA in FISH analysis. The chromosomes were counterstained with 10 ml of the DNAbinding dye 2-(4-amidinophenyl)-6-indolecarbamidine-dihydrochloride (DAPI) (Vysis) in antifade mounting solution for 5 min at 371C Hybridization signals were analysed by Zeiss Axioskop fluorescence microscope (Go¨ttingen, Germany).
Transformation, colony-forming efficiency, morphology, and tumorigenicity HCCR-2-transfected NIH/3T3 cells were maintained in culture for 4-5 weeks with the corresponding media replaced every 3 days and monitored microscopically. Transformed cell aggregates, foci, were counted by visual examination starting 2-3 weeks after transfection and the transformation efficiencies (i.e., the number of foci per microgram of DNA transfected) were determined. NIH/3T3 nontransformed cells were seeded in parallel. Individual foci were then plated separately and cultivated for 1 month for immortalization.
Colony-forming efficiency in soft agar was determined as described previously (Buick et al., 1980) with minor modifications. NIH/3T3 cells transfected with HCCR-2 (5 Â 10 3 cells) were suspended in a 1 ml mixture containing 0.3% noble agar (Difco Laboratories Inc., Detroit, MI, USA), complete medium and 10% FBS, and layered on a 2 ml solidified base of 0.6% noble agar in complete medium with 10% FBS in 35 mm plates. All samples were plated in quadruplicate. The number of cell colonies (450 cells/cluster) was counted between days 21 and 28 after plating. The diameters of colonies with a diameter greater than 100 mm were determined with a measuring reticle in the microscope. Selected colonies were physically isolated from the plates using micropipet and dispersed with trypsin. Colonies grown in culture dishes were established as cell lines and were injected into nude mice to test the capability for tumor growth of the transformed cells.
To examine cell morphologies, clones of NIH/3T3 cells stably transfected with the HCCR-2 gene were grown to approximately 70% of confluency in culture flasks, and photographed by Olympus (Inha, Japan) phase-contrast microscopy (magnification, Â 100).
The in vivo studies were approved by the Ethics Committee of our institution. Mice were given filtered tap water ad libitum in accordance with Guide for the Care and Use of Laboratory Animals (NIH). To assess in vivo tumorigenicity, NIH/3T3 cells (5 Â 10 6 cells) stably transfected with the HCCR-2 gene were injected subcutaneously into the posterior lateral aspect of the trunk of 5-week-old athymic nu/nu female BALB/c mice. Mice injected with NIH/3T3 cells transfected with the HCCR-2 gene were killed when the tumors reached 1.5-2.5 cm in diameter, approximately after 4 weeks. Mice injected with vector-transfected cells were killed after 4 weeks. Each group consisted of 15 mice. The size of the tumors was measured daily for 4-5 weeks.
Electron microscopy
For transmission electron microscopy, NIH/3T3 cells stably transfected with the HCCR-2 gene or tumors isolated from nude mice were fixed with a mixture of 2% paraformaldehyde and 2.5% glutaraldehyde (Merck & Co., Inc., Rahway, NJ, USA) in 0.2 m phosphate buffer (pH 7.4) for 4 h at 41C, and then with 1% osmium tetroxide (Merck) for 1 h at 41C. Specimens were sequentially dehydrated in a graded series of ethanol and embedded in Epon 812 (Kim et al., 1996b) . Ultrathin sections (50-70 nm thick) were stained with uranyl acetate and lead citrate (Kim et al., 1996b) and photographed with a transmission electron microscope (JEOL 1200 EX; Tokyo, Japan).
Northern blot analysis and in situ hybridization
Total RNA was extracted from fresh human tissues and cell lines using RNeasy total RNA kit (Qiagen). Northern blot analysis was carried out, in which 20 mg of denatured total RNA was electrophoresed on a 1.0% formaldehyde agarose gel and transferred to a nylon membrane (Roche Diagnostics GmbH, Mannheim, Germany). The mRNA expression of HCCR-1 and HCCR-2 was also assessed in normal human tissues and a variety of human cancer cell lines with the use of prepared membranes were obtained from Clontech (Palo Alto, CA, USA) and processed as recommended by the supplier. Human b-actin cDNA control probe provided by Clontech was used as a loading control. All blots were hybridized with the randomly primed [ 32 P]-labeled HCCR-2 partial cDNA probe (the CC214 fragment). Hybridization and washing conditions have been described elsewhere (Sambrook et al., 1989) .
For in situ hybridization, cervical cancer tissues were fixed in a buffer containing periodate-lysine-2% paraformaldehyde (McLean and Nakane, 1974) , embedded in wax (Ahn et al., 1991) and sectioned (5 mm). After the sections were dewaxed, samples were postfixed in 4% paraformaldehyde for 10 min, and treated with 0.2 n HCI for 20 min. Then samples were deproteinated with proteinase K (5 mg/ml) for 10 min at room temperature. Prehybridization and hybridization were performed at 531C for 1 and 15 h, respectively. The prehybridization buffer contained 50% formamide, 4 Â SSC, 10% dextran sulfate, 1 Â Denhardt's solution, and 1 mg/ml of salmon sperm DNA. The hybridization buffer was identical to the prehybridization buffer, with the exception that salmon sperm DNA was substituted with digoxigenin-labeled HCCR-2 riboprobe (150 ng/ml). After posthybridization washes, sections were incubated with antidigoxigenin antiserum conjugated with alkaline phosphatase (Roche Diagnostics GmbH), and histochemical detection was performed with the use of nitroblue tetrazolium (NBT)/bromochloroindolyl phosphate (BCIP) mixture (Roche Diagnostics GmbH). The HCCR-2 cDNA in the pGEM-T Easy vector (Promega, Madison, WI, USA) was used to generate sense and antisense single-stranded RNA probes for hybridization using an in vitro transcription kit (Roche Diagnostics GmbH). For digoxigenin-labeled probe, 200 ng of recombinant plasmid containing HCCR-2 insert was linearized by restriction digestion with either SalI or SphI to generate sense and antisense transcripts. Using the DIG RNA Labeling Kit (Roche Diagnostics GmbH), riboprobes were generated with SP6 and T7 RNA polymerase for 2 h at 371C in 1 Â transcription buffer (Roche Diagnostics GmbH). No signals were detected when the sense probe was used as a negative control.
Western blot analysis, immunohistochemistry, and tissue staining
For Western blot analysis, cells (5 Â 10 6 cells) isolated from various cell lines, noncancerous and cancer tissues were lysed in Laemmli sample buffer (Sambrook et al., 1989) . Equivalent volumes of cell lysates containing 20 mg of total protein were loaded on 10% SDS-polyacrylamide gels and separated by electrophoresis. For tissues extraction, it was homogenized in a lysis buffer and the homogenate was clarified by centrifugation at 5000 g for 10 min. The supernatant was used for experiment. Protein samples were then transferred to nitrocellulose membranes. The blots were incubated with polyclonal anti-HCCR-2 serum and developed with the enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech., Uppsala, Sweden). Monoclonal anti-p53 antibody DO-7 (Novo-Castra Lab., UK), Ab 5 (amino acids [aa] 37-45; Lab Vision, Fremont, CA, USA), monoclonal anti-MDM2 (Ab-1, Oncogene Research Products, Cambridge, MA, USA), and monoclonal anti-p21 (Ab-1, Oncogene Research Products) were used for Western blot analysis.
For immunohistochemistry, cryosections (5 mm thick) of human normal and cancer tissues were used. The sections were deparaffinized with xylene and ethanol. After washing with tap water, the sections were treated with methanolic H 2 O 2 for 30 min. Before incubation with primary antibodies, the sections were permeabilized by incubation in 0.5% Triton X-100 in phosphate-buffered saline (PBS) for 15 min and then blocked with normal goat serum for 15 min. The sections were incubated with polyclonal anti-HCCR-2 antibody for 2 h at room temperature. After three washes with PBS, the sections were sequentially incubated with biotinylated species-specific secondary antibodies (Vector Laboratories, Burlington, CA, USA) for 1 h at room temperature, and then avidin and biotinylated horseradish peroxidase according to the manufacturer's recommendations. Aminoethyl carbozole (AEC) was used as the chromogen. After immunostaining, sections were counterstained with hematoxylin. Sections were photographed on an Olympus photomicroscope (Inha, Japan). Reticulin fibers were stained according to the Wilder's method (Puchtler and Waldrop, 1978) .
